Beyond Air Reports Financial Results and Provides Corporate Update
Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026 Record quarterly revenue of $2.3 million, representing approximately 28% year-over-year growth, reflecting continued adoption of first-generation LungFit PH PM
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The Q3 results show accelerating revenue growth and cost reductions, but the reaffirmed guidance suggests management sees near‑term revenue ceiling until FDA approval of the next‑gen system.
Market read
Beyond Air's earnings release provides fresh data for biotech traders but limited actionable insight due to unchanged guidance.
What to watch
Potential upside if the second‑generation LungFit PH receives FDA approval, which could dramatically expand revenue.
Beyond Air reports quarterly revenue of $2.3 million, up approximately 28% year over year, and a net loss of $7.8 million attributable to common stockholders
Revenue grew approximately 28% year over year and the operating loss narrowed, but the company still reported a net loss, interest and finance expense rose to $(1,504) thousand from $(639) thousand, and the filing's risk language refers to the company's history of losses and substantial doubt about its ability to continue as a going concern. Second-generation system approval remains pending.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenues, three months ended September 30, 2026GAAP | $2.32M | 31% | approximately 28% |
| Cost of revenues, three months ended September 30, 2026GAAP | $2.13M | – | – |
| Gross profit (loss), three months ended September 30, 2026GAAP | $197K | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $1.58M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $4.59M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $6.17M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$5.97M | – | – |
| Dividend/investment income, three months ended September 30, 2026GAAP | $93K | – | – |
| Interest and finance expense, three months ended September 30, 2026GAAP | −$1.50M | – | – |
| Loss on extinguishment of debt, three months ended September 30, 2026GAAP | −$252K | – | – |
| Loss on contract manufacturer's inventory obsolescence, three months ended September 30, 2026GAAP | −$567K | – | – |
| Total other expense, three months ended September 30, 2026GAAP | −$2.2M | – | – |
| Loss before income taxes, three months ended September 30, 2026GAAP | −$8.18M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$8.18M | – | – |
| Net loss attributable to Beyond Air, Inc., three months ended September 30, 2026GAAP | −$7.82M | – | – |
| Net basic and diluted loss per share attributable to Beyond Air, Inc., three months ended September 30, 2026GAAP | $(3.76) per basic and diluted share | – | – |
| Revenues, six months ended September 30, 2026GAAP | $4.09M | – | – |
| Cost of revenues, six months ended September 30, 2026GAAP | $3.67M | – | – |
| Gross profit (loss), six months ended September 30, 2026GAAP | $422K | – | – |
| Research and development expenses, six months ended September 30, 2026GAAP | $3.54M | – | – |
| Selling, general and administrative expenses, six months ended September 30, 2026GAAP | $9.47M | – | – |
| Total operating expenses, six months ended September 30, 2026GAAP | $13.01M | – | – |
| Loss from operations, six months ended September 30, 2026GAAP | −$12.59M | – | – |
| Dividend/investment income, six months ended September 30, 2026GAAP | $196K | – | – |
| Interest and finance expense, six months ended September 30, 2026GAAP | −$3.00M | – | – |
| Loss on extinguishment of debt, six months ended September 30, 2026GAAP | −$405K | – | – |
| Loss on contract manufacturer's inventory obsolescence, six months ended September 30, 2026GAAP | −$567K | – | – |
| Total other expense, six months ended September 30, 2026GAAP | −$3.74M | – | – |
| Loss before income taxes, six months ended September 30, 2026GAAP | −$16.33M | – | – |
| Net loss, six months ended September 30, 2026GAAP | −$16.33M | – | – |
| Net loss attributable to Beyond Air, Inc., six months ended September 30, 2026GAAP | −$15.75M | – | – |
| Net basic and diluted loss per share attributable to Beyond Air, Inc., six months ended September 30, 2026GAAP | $(11.22) per basic and diluted share | – | – |
Calendar year 2026 and calendar year 2027 (reaffirmed in this filing) outlook
- RevenueCY2026: $8 million, excludes revenue from the second-generation LungFit PH system; CY2027: $16 million to $18 million, includes anticipated revenue from the second-generation system, pending FDA approval
- NoteThe company reaffirms its previously issued revenue guidance. The filing does not print a prior range for comparison.
- NoteCY2027 guidance is contingent on FDA approval of the second-generation LungFit PH system.
Capital returns
- The filing reports no share repurchases or dividends.
- The filing states that a one-for-twenty reverse stock split occurred in July 2026 and that prior period results have been adjusted for it.
- Additional paid-in capital was $340,604 thousand at September 30, 2026, compared with $325,588 thousand at March 31, 2026.
What drove it
- Revenue rose to $2,324 thousand from $1,818 thousand. The company attributes the commercial momentum to adoption of its first-generation LungFit PH system and states it is executing an enhanced commercial strategy for that system.
- The company attributes the decrease in research and development expenses primarily to lower costs related to the second-generation LungFit PH, stating that the majority of development is complete.
- The company attributes the decrease in SG&A primarily to lower stock-based compensation costs, partially offset by increased salaries in its sales organization as it builds out its commercial team.
- The company attributes the increase in other expense primarily to an increase in outstanding debt and related interest expense, in addition to a charge for scrapped materials. The statement line 'Loss on contract manufacturer's inventory obsolescence' is $(567) thousand for the quarter.
- The company states its US pipeline is experiencing expansion and that it has received high receptivity to its technology, and that the new account wins and renewals reflect customer satisfaction. The filing does not quantify these pipeline metrics.
Concerns
- Net loss attributable to Beyond Air, Inc. was $(7,818) thousand for the quarter, and the filing contains going concern language in its forward-looking statements.
- Interest and finance expense rose to $(1,504) thousand from $(639) thousand, and long-term debt, net increased to $21,982 thousand from $21,639 thousand at March 31, 2026.
- The second-generation LungFit PH system remains under FDA review. The PMA supplement was submitted in June 2025 and approval, transport labeling and launch are not assured, per the filing's risk factors.
- The company does not plan to allocate resources to further development of LungFit GO until the commercial launch of the second-generation system is well established, following FDA approval.
- A loss on extinguishment of debt of $(252) thousand for the quarter and $(405) thousand for six months is reported.
- Total stockholders' equity declined to $6,124 thousand from $6,210 thousand at March 31, 2026.
- The CY2027 guidance depends on FDA approval of the second-generation system, and the filing says that the company's ability to achieve its revenue guidance rests on assumptions that may not be realized.
What to watch
- Completion of the audit-readiness process, which the CEO expects in mid-December, followed by FDA inspections and final approval of the second-generation LungFit PH PMA supplement.
- Whether revenue reaches the reaffirmed CY2026 guidance of $8 million, which excludes the second-generation system.
- Closing of the NeuroNOS transaction with UNIVO Pharmaceutical Industries Ltd. and its conditions, as described in the filing.
- Financing arrangements, going concern disclosure and debt servicing, given the going concern language and the rise in interest and finance expense.
- The Form 10-K/T for the nine-month transition period ending December 31, 2026, which the company says it expects to file, after its fiscal year end changes from March 31 to December 31.
- Strategic arrangements for Beyond Cancer, which the company says it is evaluating.
Balance sheet and cash flow
- The company reported cash, cash equivalents, restricted cash and marketable securities of $18.5 million at September 30, 2026, including $2.7 million of cash held by NeuroNOS within current assets held for sale and $0.7 million of cash held by Beyond Cancer.
- Balance sheet at September 30, 2026: cash and cash equivalents $5,397 thousand (March 31, 2026: $6,740 thousand); marketable securities $5,652 thousand (March 31, 2026: $4,901 thousand); restricted cash $4,832 thousand (March 31, 2026: $5,622 thousand).
- Long-term debt, net: $21,982 thousand at September 30, 2026 (March 31, 2026: $21,639 thousand). Loans payable, current portion: $58 thousand (March 31, 2026: $401 thousand).
- Total assets: $36,255 thousand at September 30, 2026 (March 31, 2026: $35,385 thousand). Total liabilities: $30,131 thousand (March 31, 2026: $29,175 thousand).
- Total stockholders' equity: $6,124 thousand at September 30, 2026 (March 31, 2026: $6,210 thousand). Accumulated deficit: $(335,324) thousand (March 31, 2026: $(319,571) thousand).
- Current assets held for sale of $3,024 thousand and current liabilities held for sale of $759 thousand are shown at September 30, 2026, related to NeuroNOS, which the company has agreed to transfer to UNIVO Pharmaceutical Industries Ltd.
- The filing does not include a cash flow statement, so operating cash flow and free cash flow are not reported.
- Forward-looking statements in the filing refer to 'the Company's history of losses and substantial doubt about its ability to continue as a going concern' and to its need for financing to satisfy debt obligations as they come due.
Analysis
Beyond Air reported revenue of $2,324 thousand for the quarter ended September 30, 2026, against $1,818 thousand a year earlier, and the company states this as approximately 28% growth and as 31% growth over the quarter ended June 30, 2026. Six-month revenue was $4,092 thousand against $3,578 thousand. The company attributes the commercial progress to its first-generation LungFit PH system and to an enhanced commercial strategy. The filing describes its US pipeline and account wins in qualitative terms only and does not print adoption counts or pricing data.
Gross profit moved to $197 thousand from $(298) thousand for the quarter, with cost of revenues of $2,127 thousand against $2,116 thousand. The filing does not print a gross margin percentage. Operating expenses fell. Research and development was $1,581 thousand against $2,450 thousand, which the company links to lower second-generation costs as most development is complete. SG&A was $4,591 thousand against $4,913 thousand, which the company links to lower stock-based compensation, partly offset by sales salary growth. Loss from operations narrowed to $(5,975) thousand from $(7,661) thousand.
Below the operating line the picture is weaker. Total other expense rose to $(2,200) thousand from $(597) thousand. Interest and finance expense was $(1,504) thousand against $(639) thousand, and the company attributes this to higher outstanding debt, with a charge for scrapped materials also cited. The filing separately shows a $(567) thousand loss on contract manufacturer inventory obsolescence and a $(252) thousand loss on extinguishment of debt. Net loss attributable to Beyond Air was $(7,818) thousand, or $(3.76) per basic and diluted share, against $(7,940) thousand, or $(24.98) per share, a year earlier. The per-share prior-year figure reflects the one-for-twenty reverse split in July 2026. All figures are GAAP. The filing reports no non-GAAP measures.
On the balance sheet, the company reports $18.5 million of cash, cash equivalents, restricted cash and marketable securities, including $2.7 million held by NeuroNOS and $0.7 million held by Beyond Cancer. Long-term debt, net was $21,982 thousand, up from $21,639 thousand at March 31, 2026, and total stockholders' equity was $6,124 thousand. The filing contains going concern language. The NeuroNOS controlling interest is shown as held for sale, and the company has agreed to transfer it to UNIVO. Guidance was reaffirmed: $8 million of CY2026 revenue excluding the second-generation system, and $16 million to $18 million for CY2027 including it, pending FDA approval. The filing does not state whether the guidance changed from a prior range.
Management, verbatim
Building on the commercial momentum we are generating with our first-generation LungFit PH system, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth, pending FDA approval.
Robert Goodman, Chief Executive Officer
We expect to complete our audit-readiness process in mid-December, and subject to FDA inspections and final approval thereafter.
Robert Goodman, Chief Executive Officer
Not in the filing
stated, not guessed- Revenue for the quarter ended June 30, 2026, needed for a printed sequential prior-quarter value on the revenue row beyond the stated 31% change.
- Prior-quarter values for all income statement lines, since the filing presents only the current quarter, the prior-year quarter and six-month periods.
- Gross margin percentage, which is not printed in the filing.
- Segment or product-line revenue breakdown, which is not printed.
- Cash flow statement, including operating cash flow, investing cash flow, financing cash flow and free cash flow.
- Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2026 or September 30, 2025 on the same $18.5 million basis.
- Prior guidance ranges, so no vs_prior_guidance comparison is possible; the filing only states that guidance was reaffirmed.
- Debt terms, interest rate, maturity schedule and covenant detail for the long-term debt.
- Calculated yoy or qoq percentage changes for lines where the filing does not print them.
- Share price reaction and analyst consensus, which are not in the documents.
- Weighted average share counts for the current quarter and prior periods, which are excluded from key metrics under the reporting rules.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Beyond Air is a commercial‑stage medical‑device and biopharma firm developing nitric‑oxide delivery systems for respiratory and oncology indications.
Ticker impact
Beyond Air reported Q3 2026 revenue of $2.3M, a 28% YoY increase, and reaffirmed FY2026 revenue guidance of $8M and FY2027 guidance of $16‑$18M.
likely modest pressure as the market prices in unchanged guidance and modest revenue growth.
The company is a micro‑cap; new revenue numbers are positive but guidance reaffirmation offers little upside catalyst.
Market effects
Provides a modest boost to the medical device/biopharma niche focused on nitric‑oxide therapies.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact given the company's small size.
Counterpoint
Investors may view the reaffirmed guidance as a sign of limited growth potential and consider short positions.
Key entities
- personRobert Goodman
CEO of Beyond Air, quoted on progress and FDA discussions.
- companyUNIVO Pharmaceutical Industries Ltd.
Acquirer of Beyond Air's controlling interest in NeuroNOS Israel Ltd.

